2015 Impact Investor Conference Cliffs Notes June
Post# of 30066
Posted On: 06/24/2015 6:14:59 AM
2015 Impact Investor Conference Cliffs Notes
June 19, 2015 at 11:00 am CT / 12:00 pm ET
Webcast: http://wsw.com/webcast/impact/ambs/
00:36 "Very pleased to be part of the panel this morning "
05:26 - "As far as the pipeline, the rich pipeline that we have, we really focused it on how do we build the value to protect what we think long term will be our most valuable asset which MANF and you basically do that by making money by developing assets and then selling them off."
05:43 - "So, in the case of Amarantus Diagnostics we are now in the process of looking at strategic alternatives we expect to make some announcements officially on progress area both from a personnel perspective as well as a capital markets perspective ."
08:45 - A little bit about Eltoprazine cause this we're shifting away from an integrated Therapeutic and Diagnostics company. We believe that they are really to separate businesses and while we been good at incubating this diagnostics business we really need to put it in the hands seasoned leadership that knows how to develop those products. So we are now focusing back on our Thearupitc pipeline starting with Eltoprazine.
26:00 - Just raided $5M in a preferred financing and we are getting ready to list on the NASDAQ likely to happen sometime over the Summer . And so our strategy now really just to focus on our completing our acquisition and executing towards our NASDAQ listing where we see a lot of potential for value creating with some of the catalyst we have going, especially this ESS product.
June 19, 2015 at 11:00 am CT / 12:00 pm ET
Webcast: http://wsw.com/webcast/impact/ambs/
00:36 "Very pleased to be part of the panel this morning "
05:26 - "As far as the pipeline, the rich pipeline that we have, we really focused it on how do we build the value to protect what we think long term will be our most valuable asset which MANF and you basically do that by making money by developing assets and then selling them off."
05:43 - "So, in the case of Amarantus Diagnostics we are now in the process of looking at strategic alternatives we expect to make some announcements officially on progress area both from a personnel perspective as well as a capital markets perspective ."
08:45 - A little bit about Eltoprazine cause this we're shifting away from an integrated Therapeutic and Diagnostics company. We believe that they are really to separate businesses and while we been good at incubating this diagnostics business we really need to put it in the hands seasoned leadership that knows how to develop those products. So we are now focusing back on our Thearupitc pipeline starting with Eltoprazine.
26:00 - Just raided $5M in a preferred financing and we are getting ready to list on the NASDAQ likely to happen sometime over the Summer . And so our strategy now really just to focus on our completing our acquisition and executing towards our NASDAQ listing where we see a lot of potential for value creating with some of the catalyst we have going, especially this ESS product.
(0)
(0)